Teclistamab ELISA Kit

Catalog No.

KDF92402

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

0.31-5 μg/mL

Sensitivity

0.156 μg/ml

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

JNJ-64007957, JNJ-7957, Ab-957, CAS: 2119595-80-9,KHF92402

Background

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia., PMID:40515863

From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies., PMID:40508128

Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States., PMID:40495704

One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn's-like inflammatory bowel disease., PMID:40450406

Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab., PMID:40421459

Teclistamab-Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma., PMID:40421450

Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results., PMID:40384938

Using bispecific antibodies in a patient with peritoneal dialysis for relapsed multiple myeloma., PMID:40356496

Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis., PMID:40352937

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium., PMID:40346049

Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract., PMID:40345961

Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma., PMID:40332715

[Immunosubstitution of patients with refractory multiple myeloma treated with teclistamab, a bispecific antibody]., PMID:40318828

Pulmonary adverse events associated with monoclonal antibodies approved for multiple myeloma: a pharmacovigilance study based on the FDA adverse event reporting system., PMID:40302414

Prolonged COVID-19 Pneumonia in Patients with Hematologic Malignancies: Clinical Significance and Serial CT Findings., PMID:40283531

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma., PMID:40268898

The first case of Teclistamab interference with serum electrophoresis and immunofixation., PMID:40241333

Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization., PMID:40233295

Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review., PMID:40227780

Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma., PMID:40225701

Teclistamab versus B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis., PMID:40207713

Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients., PMID:40199861

Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal Impairment., PMID:40198766

Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain., PMID:40193043

Characteristics of second primary malignancies following bispecific antibodies therapy., PMID:40187754

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study., PMID:40175336

Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis., PMID:40113913

Teclistamab therapy for refractory type 1 cryoglobulinemia., PMID:40109179

Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System., PMID:40095047

Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review., PMID:40052837

Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing., PMID:40048741

Teclistamab for relapsed or refractory multiple myeloma., PMID:40040734

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma., PMID:40038247

Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation., PMID:40000264

Synergistic effect of teclistamab with PD-1 inhibition: a case of acute interstitial nephritis with dual immunotherapy., PMID:39974847

Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma., PMID:39911104

Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead., PMID:39880754

Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma., PMID:39861781

Injection site reaction to teclistamab in a patient with multiple myeloma., PMID:39845465

Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era., PMID:39809660

Incidence of Acute Kidney Injury in Relapsed and Refractory Multiple Myeloma treated with Teclistamab versus CAR T-cells., PMID:39805729

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma., PMID:39778168

Teclistamab as Successful Treatment of Relapsed TEMPI Syndrome., PMID:39774321

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis., PMID:39756041

Update on B-cell maturation antigen-directed therapies in AL amyloidosis., PMID:39748220

Practical insights into bispecific antibody therapy in multiple myeloma., PMID:39729045

Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration., PMID:39705632

Recurrent Cardiac Tamponade from Multiple Myeloma While Receiving Teclistamab., PMID:39691339

Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives., PMID:39676006

Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1., PMID:39660861

Document Download

Teclistamab ELISA Kit.pdf